Agonists for PPARγ, such as thiazolidinediones that are in use as a treatment for type 2 diabetes mellitus, have been shown to have inhibitory effects on platelet signaling and activation 6, 7, 8, 18, 19, which could underlie the reported reduction in atherosclerosis, reduced inflammation and cardio‐protective effects in patients treated with PPARγ agonists 12, 13, 16, 20, 21, 22, 23, 24. This evidence concerns the gene PPARG and diabetes mellitus.